#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4.
1-1	0-2	4.	_	_	_	_

#Text=Discussion
2-1	3-13	Discussion	abstract	new	_	_

#Text=Here , we describe a link between fructose and NO levels in the NTS , as well as its association with baroreflex sensitivity and activation of the CNS .
3-1	14-18	Here	_	_	_	_
3-2	19-20	,	_	_	_	_
3-3	21-23	we	person	acc	ana	4-1
3-4	24-32	describe	_	_	_	_
3-5	33-34	a	abstract[3]	new[3]	coref	7-6[45_3]
3-6	35-39	link	abstract[3]	new[3]	_	_
3-7	40-47	between	abstract[3]	new[3]	_	_
3-8	48-56	fructose	abstract[3]|abstract|abstract[6]	new[3]|new|new[6]	coref|coref	4-6|5-5[28_6]
3-9	57-60	and	abstract[3]|abstract[6]	new[3]|new[6]	_	_
3-10	61-63	NO	abstract[3]|substance|abstract[6]	new[3]|new|new[6]	_	_
3-11	64-70	levels	abstract[3]|abstract[6]	new[3]|new[6]	_	_
3-12	71-73	in	abstract[3]|abstract[6]	new[3]|new[6]	_	_
3-13	74-77	the	abstract[3]|abstract[6]|abstract[7]	new[3]|new[6]|new[7]	ana	3-19[0_7]
3-14	78-81	NTS	abstract[3]|abstract[6]|abstract[7]	new[3]|new[6]|new[7]	_	_
3-15	82-83	,	_	_	_	_
3-16	84-86	as	_	_	_	_
3-17	87-91	well	_	_	_	_
3-18	92-94	as	_	_	_	_
3-19	95-98	its	abstract|abstract[9]	giv|new[9]	coref	30-13[202_0]
3-20	99-110	association	abstract[9]	new[9]	_	_
3-21	111-115	with	abstract[9]	new[9]	_	_
3-22	116-126	baroreflex	abstract[9]|place|abstract[11]|abstract[12]	new[9]|new|new[11]|new[12]	coref|coref	4-20|29-11[194_12]
3-23	127-138	sensitivity	abstract[9]|abstract[11]|abstract[12]	new[9]|new[11]|new[12]	_	_
3-24	139-142	and	abstract[9]|abstract[12]	new[9]|new[12]	_	_
3-25	143-153	activation	abstract[9]|abstract[12]|event[13]	new[9]|new[12]|new[13]	coref	5-24[34_13]
3-26	154-156	of	abstract[9]|abstract[12]|event[13]	new[9]|new[12]|new[13]	_	_
3-27	157-160	the	abstract[9]|abstract[12]|event[13]|abstract[14]	new[9]|new[12]|new[13]|new[14]	_	_
3-28	161-164	CNS	abstract[9]|abstract[12]|event[13]|abstract[14]	new[9]|new[12]|new[13]|new[14]	_	_
3-29	165-166	.	_	_	_	_

#Text=Our findings showed that excessive fructose consumption increased BP and renal SNA , decreased NO bioavailability , and impaired baroreflex response .
4-1	167-170	Our	person|abstract[16]	giv|new[16]	ana	20-7
4-2	171-179	findings	abstract[16]	new[16]	_	_
4-3	180-186	showed	_	_	_	_
4-4	187-191	that	_	_	_	_
4-5	192-201	excessive	abstract[18]	new[18]	coref	6-19[42_18]
4-6	202-210	fructose	abstract|abstract[18]	giv|new[18]	coref	5-2
4-7	211-222	consumption	abstract[18]	new[18]	_	_
4-8	223-232	increased	event	new	none|none	4-8[0_107]|5-4
4-9	233-235	BP	abstract	new	coref	5-10
4-10	236-239	and	_	_	_	_
4-11	240-245	renal	abstract[20]	new[20]	coref	5-14[0_20]
4-12	246-249	SNA	abstract[20]	new[20]	_	_
4-13	250-251	,	_	_	_	_
4-14	252-261	decreased	_	_	_	_
4-15	262-264	NO	abstract[21]	new[21]	_	_
4-16	265-280	bioavailability	abstract[21]	new[21]	_	_
4-17	281-282	,	_	_	_	_
4-18	283-286	and	_	_	_	_
4-19	287-295	impaired	_	_	_	_
4-20	296-306	baroreflex	place|event[23]	giv|new[23]	coref	23-2
4-21	307-315	response	event[23]	new[23]	_	_
4-22	316-317	.	_	_	_	_

#Text=Excessive fructose intake increased serum triglycerides levels and induced BP elevation by stimulating SNA ; however , alleviation of hypertriglyceridemia did not attenuate sympathetic activation and only slightly lowered BP .
5-1	318-327	Excessive	event[25]	new[25]	coref	9-16[64_25]
5-2	328-336	fructose	abstract|event[25]	giv|new[25]	coref	6-20
5-3	337-343	intake	event[25]	new[25]	_	_
5-4	344-353	increased	event	new	none	9-11
5-5	354-359	serum	substance|abstract[27]|abstract[28]	new|new[27]|giv[28]	coref|coref	13-16[102_28]|17-6
5-6	360-373	triglycerides	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
5-7	374-380	levels	abstract[28]	giv[28]	_	_
5-8	381-384	and	_	_	_	_
5-9	385-392	induced	_	_	_	_
5-10	393-395	BP	abstract|abstract[30]	giv|new[30]	coref	4-8
5-11	396-405	elevation	abstract[30]	new[30]	_	_
5-12	406-408	by	_	_	_	_
5-13	409-420	stimulating	_	_	_	_
5-14	421-424	SNA	abstract	giv	coref	6-8
5-15	425-426	;	_	_	_	_
5-16	427-434	however	_	_	_	_
5-17	435-436	,	_	_	_	_
5-18	437-448	alleviation	abstract[32]	new[32]	_	_
5-19	449-451	of	abstract[32]	new[32]	_	_
5-20	452-472	hypertriglyceridemia	abstract[32]|abstract	new[32]|new	coref	11-12
5-21	473-476	did	_	_	_	_
5-22	477-480	not	_	_	_	_
5-23	481-490	attenuate	_	_	_	_
5-24	491-502	sympathetic	event[34]	giv[34]	_	_
5-25	503-513	activation	event[34]	giv[34]	_	_
5-26	514-517	and	_	_	_	_
5-27	518-522	only	_	_	_	_
5-28	523-531	slightly	_	_	_	_
5-29	532-539	lowered	_	_	_	_
5-30	540-542	BP	abstract	giv	ana	6-1
5-31	543-544	.	_	_	_	_

#Text=It was suggested that , mechanistically , SNA played a role in modulating changes in BP due to increased fructose consumption through another unknown pathway .
6-1	545-547	It	abstract	giv	coref	6-16
6-2	548-551	was	_	_	_	_
6-3	552-561	suggested	_	_	_	_
6-4	562-566	that	_	_	_	_
6-5	567-568	,	_	_	_	_
6-6	569-584	mechanistically	_	_	_	_
6-7	585-586	,	_	_	_	_
6-8	587-590	SNA	abstract	giv	coref	17-22[121_0]
6-9	591-597	played	_	_	_	_
6-10	598-599	a	abstract[38]	new[38]	_	_
6-11	600-604	role	abstract[38]	new[38]	_	_
6-12	605-607	in	_	_	_	_
6-13	608-618	modulating	_	_	_	_
6-14	619-626	changes	abstract[39]	new[39]	_	_
6-15	627-629	in	abstract[39]	new[39]	_	_
6-16	630-632	BP	abstract[39]|abstract	new[39]|giv	coref	8-23
6-17	633-636	due	_	_	_	_
6-18	637-639	to	_	_	_	_
6-19	640-649	increased	abstract[42]	giv[42]	coref	7-9[47_42]
6-20	650-658	fructose	abstract|abstract[42]	giv|giv[42]	coref	7-9
6-21	659-670	consumption	abstract[42]	giv[42]	_	_
6-22	671-678	through	_	_	_	_
6-23	679-686	another	abstract[43]	new[43]	_	_
6-24	687-694	unknown	abstract[43]	new[43]	_	_
6-25	695-702	pathway	abstract[43]	new[43]	_	_
6-26	703-704	.	_	_	_	_

#Text=Epidemiological studies have hinted at a link between fructose consumption and elevated blood pressure .
7-1	705-720	Epidemiological	abstract[44]	new[44]	coref	11-1[82_44]
7-2	721-728	studies	abstract[44]	new[44]	_	_
7-3	729-733	have	_	_	_	_
7-4	734-740	hinted	_	_	_	_
7-5	741-743	at	_	_	_	_
7-6	744-745	a	abstract[45]	giv[45]	_	_
7-7	746-750	link	abstract[45]	giv[45]	_	_
7-8	751-758	between	abstract[45]	giv[45]	_	_
7-9	759-767	fructose	abstract[45]|abstract|abstract[47]	giv[45]|giv|giv[47]	coref|coref	8-6[50_0]|16-5[109_47]
7-10	768-779	consumption	abstract[45]|abstract[47]	giv[45]|giv[47]	_	_
7-11	780-783	and	abstract[45]	giv[45]	_	_
7-12	784-792	elevated	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-13	793-798	blood	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-14	799-807	pressure	abstract[45]|abstract[48]	giv[45]|new[48]	_	_
7-15	808-809	.	_	_	_	_

#Text=Jalal et al. reported that excess dietary fructose ( ≥74 g/day ) in the form of added sugar was associated with higher BP values in adults in the United States who did not have a history of hypertension .
8-1	810-815	Jalal	person	new	_	_
8-2	816-818	et	_	_	_	_
8-3	819-822	al.	_	_	_	_
8-4	823-831	reported	_	_	_	_
8-5	832-836	that	_	_	_	_
8-6	837-843	excess	abstract[50]	giv[50]	appos	8-10[51_50]
8-7	844-851	dietary	abstract[50]	giv[50]	_	_
8-8	852-860	fructose	abstract[50]	giv[50]	_	_
8-9	861-862	(	_	_	_	_
8-10	863-866	≥74	abstract[51]	giv[51]	coref	13-6[0_51]
8-11	867-872	g/day	abstract[51]	giv[51]	_	_
8-12	873-874	)	_	_	_	_
8-13	875-877	in	_	_	_	_
8-14	878-881	the	substance[52]	new[52]	_	_
8-15	882-886	form	substance[52]	new[52]	_	_
8-16	887-889	of	substance[52]	new[52]	_	_
8-17	890-895	added	substance[52]|substance[53]	new[52]|new[53]	_	_
8-18	896-901	sugar	substance[52]|substance[53]	new[52]|new[53]	_	_
8-19	902-905	was	_	_	_	_
8-20	906-916	associated	_	_	_	_
8-21	917-921	with	_	_	_	_
8-22	922-928	higher	abstract[55]	new[55]	_	_
8-23	929-931	BP	abstract|abstract[55]	giv|new[55]	coref	11-24[90_0]
8-24	932-938	values	abstract[55]	new[55]	_	_
8-25	939-941	in	abstract[55]	new[55]	_	_
8-26	942-948	adults	abstract[55]|person[56]	new[55]|new[56]	coref	10-6[68_56]
8-27	949-951	in	abstract[55]|person[56]	new[55]|new[56]	_	_
8-28	952-955	the	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	coref	10-8[69_57]
8-29	956-962	United	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-30	963-969	States	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-31	970-973	who	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-32	974-977	did	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-33	978-981	not	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-34	982-986	have	abstract[55]|person[56]|place[57]	new[55]|new[56]|new[57]	_	_
8-35	987-988	a	abstract[55]|person[56]|place[57]|abstract[58]	new[55]|new[56]|new[57]|new[58]	_	_
8-36	989-996	history	abstract[55]|person[56]|place[57]|abstract[58]	new[55]|new[56]|new[57]|new[58]	_	_
8-37	997-999	of	abstract[55]|person[56]|place[57]|abstract[58]	new[55]|new[56]|new[57]|new[58]	_	_
8-38	1000-1012	hypertension	abstract[55]|person[56]|place[57]|abstract[58]|abstract	new[55]|new[56]|new[57]|new[58]|new	coref	18-7
8-39	1013-1014	.	_	_	_	_

#Text=Similarly , a study of 4867 adolescents found that SBP rose by 2 mmHg following the intake of sugar-sweetened beverages from the lowest to the highest category .
9-1	1015-1024	Similarly	_	_	_	_
9-2	1025-1026	,	_	_	_	_
9-3	1027-1028	a	abstract[60]	new[60]	coref	10-2[67_60]
9-4	1029-1034	study	abstract[60]	new[60]	_	_
9-5	1035-1037	of	abstract[60]	new[60]	_	_
9-6	1038-1042	4867	abstract[60]|person[61]	new[60]|new[61]	_	_
9-7	1043-1054	adolescents	abstract[60]|person[61]	new[60]|new[61]	_	_
9-8	1055-1060	found	_	_	_	_
9-9	1061-1065	that	_	_	_	_
9-10	1066-1069	SBP	abstract	new	coref	10-33
9-11	1070-1074	rose	event	new	coref	16-1[107_0]
9-12	1075-1077	by	_	_	_	_
9-13	1078-1079	2	abstract[63]	new[63]	coref	10-30[0_63]
9-14	1080-1084	mmHg	abstract[63]	new[63]	_	_
9-15	1085-1094	following	_	_	_	_
9-16	1095-1098	the	event[64]	giv[64]	_	_
9-17	1099-1105	intake	event[64]	giv[64]	_	_
9-18	1106-1108	of	event[64]	giv[64]	_	_
9-19	1109-1124	sugar-sweetened	event[64]|substance[65]	giv[64]|new[65]	_	_
9-20	1125-1134	beverages	event[64]|substance[65]	giv[64]|new[65]	_	_
9-21	1135-1139	from	event[64]|substance[65]	giv[64]|new[65]	_	_
9-22	1140-1143	the	event[64]|substance[65]	giv[64]|new[65]	_	_
9-23	1144-1150	lowest	event[64]|substance[65]	giv[64]|new[65]	_	_
9-24	1151-1153	to	event[64]|substance[65]	giv[64]|new[65]	_	_
9-25	1154-1157	the	event[64]|substance[65]|abstract[66]	giv[64]|new[65]|new[66]	_	_
9-26	1158-1165	highest	event[64]|substance[65]|abstract[66]	giv[64]|new[65]|new[66]	_	_
9-27	1166-1174	category	event[64]|substance[65]|abstract[66]	giv[64]|new[65]|new[66]	_	_
9-28	1175-1176	.	_	_	_	_

#Text=In a prospective study involving adults in the United States , Chen et al. found that intake of one less sugar-sweetened beverage per day was associated with a 1.8 mmHg reduction in SBP and a 1.1 mmHg reduction in DBP over 18 months .
10-1	1177-1179	In	_	_	_	_
10-2	1180-1181	a	abstract[67]	giv[67]	coref	13-2[96_67]
10-3	1182-1193	prospective	abstract[67]	giv[67]	_	_
10-4	1194-1199	study	abstract[67]	giv[67]	_	_
10-5	1200-1209	involving	abstract[67]	giv[67]	_	_
10-6	1210-1216	adults	abstract[67]|person[68]	giv[67]|giv[68]	_	_
10-7	1217-1219	in	abstract[67]|person[68]	giv[67]|giv[68]	_	_
10-8	1220-1223	the	abstract[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
10-9	1224-1230	United	abstract[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
10-10	1231-1237	States	abstract[67]|person[68]|place[69]	giv[67]|giv[68]|giv[69]	_	_
10-11	1238-1239	,	_	_	_	_
10-12	1240-1244	Chen	person	new	_	_
10-13	1245-1247	et	_	_	_	_
10-14	1248-1251	al.	_	_	_	_
10-15	1252-1257	found	_	_	_	_
10-16	1258-1262	that	_	_	_	_
10-17	1263-1269	intake	event[71]	new[71]	coref	13-5[98_71]
10-18	1270-1272	of	event[71]	new[71]	_	_
10-19	1273-1276	one	event[71]|substance[72]	new[71]|new[72]	_	_
10-20	1277-1281	less	event[71]|substance[72]	new[71]|new[72]	_	_
10-21	1282-1297	sugar-sweetened	event[71]|substance[72]	new[71]|new[72]	_	_
10-22	1298-1306	beverage	event[71]|substance[72]	new[71]|new[72]	_	_
10-23	1307-1310	per	event[71]|substance[72]	new[71]|new[72]	_	_
10-24	1311-1314	day	event[71]|substance[72]|time	new[71]|new[72]|new	coref	13-27[105_0]
10-25	1315-1318	was	_	_	_	_
10-26	1319-1329	associated	_	_	_	_
10-27	1330-1334	with	_	_	_	_
10-28	1335-1336	a	abstract[75]	new[75]	_	_
10-29	1337-1340	1.8	abstract[75]	new[75]	_	_
10-30	1341-1345	mmHg	abstract|abstract[75]	giv|new[75]	coref	10-37
10-31	1346-1355	reduction	abstract[75]	new[75]	_	_
10-32	1356-1358	in	abstract[75]	new[75]	_	_
10-33	1359-1362	SBP	abstract[75]|abstract	new[75]|giv	_	_
10-34	1363-1366	and	_	_	_	_
10-35	1367-1368	a	abstract[78]	new[78]	_	_
10-36	1369-1372	1.1	abstract[78]	new[78]	_	_
10-37	1373-1377	mmHg	abstract|abstract[78]	giv|new[78]	_	_
10-38	1378-1387	reduction	abstract[78]	new[78]	_	_
10-39	1388-1390	in	abstract[78]	new[78]	_	_
10-40	1391-1394	DBP	abstract[78]|abstract	new[78]|new	_	_
10-41	1395-1399	over	_	_	_	_
10-42	1400-1402	18	time[80]	new[80]	_	_
10-43	1403-1409	months	time[80]	new[80]	_	_
10-44	1410-1411	.	_	_	_	_

#Text=Some animal studies showed that a high-fructose diet was associated with hypertriglyceridemia , hyperinsulinemia , impaired glucose tolerance , insulin resistance , and increased BP and body weight .
11-1	1412-1416	Some	abstract[82]	giv[82]	_	_
11-2	1417-1423	animal	animal|abstract[82]	new|giv[82]	_	_
11-3	1424-1431	studies	abstract[82]	giv[82]	_	_
11-4	1432-1438	showed	_	_	_	_
11-5	1439-1443	that	_	_	_	_
11-6	1444-1445	a	abstract[83]	new[83]	_	_
11-7	1446-1459	high-fructose	abstract[83]	new[83]	_	_
11-8	1460-1464	diet	abstract[83]	new[83]	_	_
11-9	1465-1468	was	_	_	_	_
11-10	1469-1479	associated	_	_	_	_
11-11	1480-1484	with	_	_	_	_
11-12	1485-1505	hypertriglyceridemia	abstract	giv	coref	25-6
11-13	1506-1507	,	_	_	_	_
11-14	1508-1524	hyperinsulinemia	abstract	new	_	_
11-15	1525-1526	,	_	_	_	_
11-16	1527-1535	impaired	abstract[87]	new[87]	_	_
11-17	1536-1543	glucose	substance|abstract[87]	new|new[87]	coref	12-13
11-18	1544-1553	tolerance	abstract[87]	new[87]	_	_
11-19	1554-1555	,	_	_	_	_
11-20	1556-1563	insulin	substance|abstract[89]	new|new[89]	_	_
11-21	1564-1574	resistance	abstract[89]	new[89]	_	_
11-22	1575-1576	,	_	_	_	_
11-23	1577-1580	and	_	_	_	_
11-24	1581-1590	increased	abstract[90]	giv[90]	coref	13-16[0_90]
11-25	1591-1593	BP	abstract[90]	giv[90]	_	_
11-26	1594-1597	and	_	_	_	_
11-27	1598-1602	body	object|abstract[92]	new|new[92]	_	_
11-28	1603-1609	weight	abstract[92]	new[92]	_	_
11-29	1610-1611	.	_	_	_	_

#Text=However , these adverse effects were not indicated with equivalent calories of glucose .
12-1	1612-1619	However	_	_	_	_
12-2	1620-1621	,	_	_	_	_
12-3	1622-1627	these	abstract[93]	new[93]	coref	24-8[161_93]
12-4	1628-1635	adverse	abstract[93]	new[93]	_	_
12-5	1636-1643	effects	abstract[93]	new[93]	_	_
12-6	1644-1648	were	_	_	_	_
12-7	1649-1652	not	_	_	_	_
12-8	1653-1662	indicated	_	_	_	_
12-9	1663-1667	with	_	_	_	_
12-10	1668-1678	equivalent	substance[94]	new[94]	_	_
12-11	1679-1687	calories	substance[94]	new[94]	_	_
12-12	1688-1690	of	substance[94]	new[94]	_	_
12-13	1691-1698	glucose	substance[94]|substance	new[94]|giv	_	_
12-14	1699-1700	.	_	_	_	_

#Text=In this study , increased fructose intake for 0 to 2 days evoked increases in BP levels , and the high BP levels were maintained until day 7 (
13-1	1701-1703	In	_	_	_	_
13-2	1704-1708	this	abstract[96]	giv[96]	coref	25-1[163_96]
13-3	1709-1714	study	abstract[96]	giv[96]	_	_
13-4	1715-1716	,	_	_	_	_
13-5	1717-1726	increased	event[98]	giv[98]	coref	30-6[199_98]
13-6	1727-1735	fructose	abstract|event[98]	giv|giv[98]	coref	16-5
13-7	1736-1742	intake	event[98]	giv[98]	_	_
13-8	1743-1746	for	event[98]	giv[98]	_	_
13-9	1747-1748	0	event[98]|time[99]	giv[98]|new[99]	_	_
13-10	1749-1751	to	event[98]|time[99]	giv[98]|new[99]	_	_
13-11	1752-1753	2	event[98]|time[99]	giv[98]|new[99]	_	_
13-12	1754-1758	days	event[98]|time[99]	giv[98]|new[99]	_	_
13-13	1759-1765	evoked	_	_	_	_
13-14	1766-1775	increases	event[100]	new[100]	_	_
13-15	1776-1778	in	event[100]	new[100]	_	_
13-16	1779-1781	BP	event[100]|abstract|abstract[102]	new[100]|giv|giv[102]	coref|coref	13-22|13-20[104_102]
13-17	1782-1788	levels	event[100]|abstract[102]	new[100]|giv[102]	_	_
13-18	1789-1790	,	_	_	_	_
13-19	1791-1794	and	_	_	_	_
13-20	1795-1798	the	abstract[104]	giv[104]	coref	17-9[119_104]
13-21	1799-1803	high	abstract[104]	giv[104]	_	_
13-22	1804-1806	BP	abstract|abstract[104]	giv|giv[104]	coref	20-28
13-23	1807-1813	levels	abstract[104]	giv[104]	_	_
13-24	1814-1818	were	_	_	_	_
13-25	1819-1829	maintained	_	_	_	_
13-26	1830-1835	until	_	_	_	_
13-27	1836-1839	day	time[105]	giv[105]	_	_
13-28	1840-1841	7	time[105]	giv[105]	_	_
13-29	1842-1843	(	_	_	_	_

#Text=Figure 2
14-1	1844-1850	Figure	abstract[106]	new[106]	_	_
14-2	1851-1852	2	abstract[106]	new[106]	_	_

#Text=) .
15-1	1853-1854	)	_	_	_	_
15-2	1855-1856	.	_	_	_	_

#Text=The great increase in fructose consumption in the last decades leads to the rapid accumulation of triglyceride in the Occidental population .
16-1	1857-1860	The	event[107]	new[107]	_	_
16-2	1861-1866	great	event[107]	new[107]	_	_
16-3	1867-1875	increase	event[107]	new[107]	_	_
16-4	1876-1878	in	event[107]	new[107]	_	_
16-5	1879-1887	fructose	event[107]|abstract|abstract[109]	new[107]|giv|giv[109]	coref|coref	18-15|18-14[126_109]
16-6	1888-1899	consumption	event[107]|abstract[109]	new[107]|giv[109]	_	_
16-7	1900-1902	in	event[107]	new[107]	_	_
16-8	1903-1906	the	event[107]|time[110]	new[107]|new[110]	_	_
16-9	1907-1911	last	event[107]|time[110]	new[107]|new[110]	_	_
16-10	1912-1919	decades	event[107]|time[110]	new[107]|new[110]	_	_
16-11	1920-1925	leads	_	_	_	_
16-12	1926-1928	to	_	_	_	_
16-13	1929-1932	the	event[111]	new[111]	_	_
16-14	1933-1938	rapid	event[111]	new[111]	_	_
16-15	1939-1951	accumulation	event[111]	new[111]	_	_
16-16	1952-1954	of	event[111]	new[111]	_	_
16-17	1955-1967	triglyceride	event[111]|substance	new[111]|new	coref	17-9
16-18	1968-1970	in	event[111]	new[111]	_	_
16-19	1971-1974	the	event[111]|animal[114]	new[111]|new[114]	_	_
16-20	1975-1985	Occidental	event[111]|organization|animal[114]	new[111]|new|new[114]	_	_
16-21	1986-1996	population	event[111]|animal[114]	new[111]|new[114]	_	_
16-22	1997-1998	.	_	_	_	_

#Text=Tran et al. reported that serum norepinephrine and triglyceride levels are significantly increased in fructose-fed hypertensive rats , as reflected by high SNA .
17-1	1999-2003	Tran	person	new	coref	18-3
17-2	2004-2006	et	_	_	_	_
17-3	2007-2010	al.	_	_	_	_
17-4	2011-2019	reported	_	_	_	_
17-5	2020-2024	that	_	_	_	_
17-6	2025-2030	serum	substance|substance[117]	giv|new[117]	coref	19-13
17-7	2031-2045	norepinephrine	substance[117]	new[117]	_	_
17-8	2046-2049	and	_	_	_	_
17-9	2050-2062	triglyceride	substance|abstract[119]	giv|giv[119]	coref|coref	19-11|30-10[201_119]
17-10	2063-2069	levels	abstract[119]	giv[119]	_	_
17-11	2070-2073	are	_	_	_	_
17-12	2074-2087	significantly	_	_	_	_
17-13	2088-2097	increased	_	_	_	_
17-14	2098-2100	in	_	_	_	_
17-15	2101-2113	fructose-fed	animal[120]	new[120]	coref	18-11[0_120]
17-16	2114-2126	hypertensive	animal[120]	new[120]	_	_
17-17	2127-2131	rats	animal[120]	new[120]	_	_
17-18	2132-2133	,	_	_	_	_
17-19	2134-2136	as	_	_	_	_
17-20	2137-2146	reflected	_	_	_	_
17-21	2147-2149	by	_	_	_	_
17-22	2150-2154	high	abstract[121]	giv[121]	coref	20-33[0_121]
17-23	2155-2158	SNA	abstract[121]	giv[121]	_	_
17-24	2159-2160	.	_	_	_	_

#Text=According to Tran et al. , hypertension can develop in rats owing to excessive fructose consumption , and the developed hypertension can be treated using a sympatholytic agent called prazosin , which blocks the α1-adrenoreceptors .
18-1	2161-2170	According	_	_	_	_
18-2	2171-2173	to	_	_	_	_
18-3	2174-2178	Tran	person	giv	_	_
18-4	2179-2181	et	_	_	_	_
18-5	2182-2185	al.	_	_	_	_
18-6	2186-2187	,	_	_	_	_
18-7	2188-2200	hypertension	abstract	giv	coref	18-19[127_0]
18-8	2201-2204	can	_	_	_	_
18-9	2205-2212	develop	event	new	coref|none	30-26[206_0]|18-9[0_206]
18-10	2213-2215	in	_	_	_	_
18-11	2216-2220	rats	animal	giv	coref	26-13[172_0]
18-12	2221-2226	owing	_	_	_	_
18-13	2227-2229	to	_	_	_	_
18-14	2230-2239	excessive	abstract[126]	giv[126]	coref	29-7[191_126]
18-15	2240-2248	fructose	abstract|abstract[126]	giv|giv[126]	coref	27-9
18-16	2249-2260	consumption	abstract[126]	giv[126]	_	_
18-17	2261-2262	,	_	_	_	_
18-18	2263-2266	and	_	_	_	_
18-19	2267-2270	the	abstract[127]	giv[127]	coref	19-1[0_127]
18-20	2271-2280	developed	abstract[127]	giv[127]	_	_
18-21	2281-2293	hypertension	abstract[127]	giv[127]	_	_
18-22	2294-2297	can	_	_	_	_
18-23	2298-2300	be	_	_	_	_
18-24	2301-2308	treated	_	_	_	_
18-25	2309-2314	using	_	_	_	_
18-26	2315-2316	a	substance[128]	new[128]	_	_
18-27	2317-2330	sympatholytic	substance[128]	new[128]	_	_
18-28	2331-2336	agent	substance[128]	new[128]	_	_
18-29	2337-2343	called	substance[128]	new[128]	_	_
18-30	2344-2352	prazosin	substance[128]|substance	new[128]|new	coref	19-4
18-31	2353-2354	,	substance[128]	new[128]	_	_
18-32	2355-2360	which	substance[128]	new[128]	_	_
18-33	2361-2367	blocks	substance[128]	new[128]	_	_
18-34	2368-2371	the	substance[128]|abstract[130]	new[128]|new[130]	_	_
18-35	2372-2390	α1-adrenoreceptors	substance[128]|abstract[130]	new[128]|new[130]	_	_
18-36	2391-2392	.	_	_	_	_

#Text=Hypertension inhibition by prazosin did not reduce the level of triglyceride in serum .
19-1	2393-2405	Hypertension	abstract|event[132]	giv|new[132]	_	_
19-2	2406-2416	inhibition	event[132]	new[132]	_	_
19-3	2417-2419	by	event[132]	new[132]	_	_
19-4	2420-2428	prazosin	event[132]|substance	new[132]|giv	_	_
19-5	2429-2432	did	_	_	_	_
19-6	2433-2436	not	_	_	_	_
19-7	2437-2443	reduce	_	_	_	_
19-8	2444-2447	the	abstract[134]	new[134]	coref	20-19[145_134]
19-9	2448-2453	level	abstract[134]	new[134]	_	_
19-10	2454-2456	of	abstract[134]	new[134]	_	_
19-11	2457-2469	triglyceride	abstract[134]|substance	new[134]|giv	coref	20-20
19-12	2470-2472	in	_	_	_	_
19-13	2473-2478	serum	substance	giv	coref	20-19
19-14	2479-2480	.	_	_	_	_

#Text=Consistent with this previous result , our data showed that the use of a DGAT1 inhibitor for inhibiting serum triglyceride level led to a slight decrease in BP but did not affect SNA (
20-1	2481-2491	Consistent	_	_	_	_
20-2	2492-2496	with	_	_	_	_
20-3	2497-2501	this	abstract[137]	new[137]	_	_
20-4	2502-2510	previous	abstract[137]	new[137]	_	_
20-5	2511-2517	result	abstract[137]	new[137]	_	_
20-6	2518-2519	,	_	_	_	_
20-7	2520-2523	our	person|abstract[139]	giv|new[139]	ana	30-1
20-8	2524-2528	data	abstract[139]	new[139]	_	_
20-9	2529-2535	showed	_	_	_	_
20-10	2536-2540	that	_	_	_	_
20-11	2541-2544	the	event[140]	new[140]	_	_
20-12	2545-2548	use	event[140]	new[140]	_	_
20-13	2549-2551	of	event[140]	new[140]	_	_
20-14	2552-2553	a	event[140]|abstract[142]	new[140]|new[142]	coref	28-9[183_142]
20-15	2554-2559	DGAT1	event[140]|abstract|abstract[142]	new[140]|new|new[142]	coref	28-10
20-16	2560-2569	inhibitor	event[140]|abstract[142]	new[140]|new[142]	_	_
20-17	2570-2573	for	event[140]|abstract[142]	new[140]|new[142]	_	_
20-18	2574-2584	inhibiting	event[140]|abstract[142]	new[140]|new[142]	_	_
20-19	2585-2590	serum	event[140]|abstract[142]|substance|abstract[145]	new[140]|new[142]|giv|giv[145]	coref	38-13[235_145]
20-20	2591-2603	triglyceride	event[140]|abstract[142]|substance|abstract[145]	new[140]|new[142]|giv|giv[145]	_	_
20-21	2604-2609	level	event[140]|abstract[142]|abstract[145]	new[140]|new[142]|giv[145]	_	_
20-22	2610-2613	led	_	_	_	_
20-23	2614-2616	to	_	_	_	_
20-24	2617-2618	a	event[146]	new[146]	_	_
20-25	2619-2625	slight	event[146]	new[146]	_	_
20-26	2626-2634	decrease	event[146]	new[146]	_	_
20-27	2635-2637	in	event[146]	new[146]	_	_
20-28	2638-2640	BP	event[146]|abstract	new[146]|giv	coref	23-19[157_0]
20-29	2641-2644	but	_	_	_	_
20-30	2645-2648	did	_	_	_	_
20-31	2649-2652	not	_	_	_	_
20-32	2653-2659	affect	_	_	_	_
20-33	2660-2663	SNA	abstract	giv	coref	27-21[180_0]
20-34	2664-2665	(	_	_	_	_

#Text=Figure 3
21-1	2666-2672	Figure	abstract[149]	new[149]	_	_
21-2	2673-2674	3	abstract[149]	new[149]	_	_

#Text=) .
22-1	2675-2676	)	_	_	_	_
22-2	2677-2678	.	_	_	_	_

#Text=The baroreflex system is an important mechanism in the regulation of heart rate , sympathetic tone , and consequently BP .
23-1	2679-2682	The	abstract[151]	new[151]	coref	23-5[152_151]
23-2	2683-2693	baroreflex	place|abstract[151]	giv|new[151]	coref	24-3
23-3	2694-2700	system	abstract[151]	new[151]	_	_
23-4	2701-2703	is	_	_	_	_
23-5	2704-2706	an	abstract[152]	giv[152]	coref	39-16[244_152]
23-6	2707-2716	important	abstract[152]	giv[152]	_	_
23-7	2717-2726	mechanism	abstract[152]	giv[152]	_	_
23-8	2727-2729	in	abstract[152]	giv[152]	_	_
23-9	2730-2733	the	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-10	2734-2744	regulation	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-11	2745-2747	of	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-12	2748-2753	heart	abstract[152]|abstract[153]|place|abstract[155]	giv[152]|new[153]|new|new[155]	_	_
23-13	2754-2758	rate	abstract[152]|abstract[153]|abstract[155]	giv[152]|new[153]|new[155]	_	_
23-14	2759-2760	,	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-15	2761-2772	sympathetic	abstract[152]|abstract[153]|abstract[156]	giv[152]|new[153]|new[156]	_	_
23-16	2773-2777	tone	abstract[152]|abstract[153]|abstract[156]	giv[152]|new[153]|new[156]	_	_
23-17	2778-2779	,	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-18	2780-2783	and	abstract[152]|abstract[153]	giv[152]|new[153]	_	_
23-19	2784-2796	consequently	abstract[152]|abstract[153]|abstract[157]	giv[152]|new[153]|giv[157]	coref	26-6[170_157]
23-20	2797-2799	BP	abstract[152]|abstract[153]|abstract[157]	giv[152]|new[153]|giv[157]	_	_
23-21	2800-2801	.	_	_	_	_

#Text=Impairment of baroreflex sensitivity is involved in the sympathoexcitatory and sympathoinhibitory effects of metabolic syndromes .
24-1	2802-2812	Impairment	abstract[158]	new[158]	_	_
24-2	2813-2815	of	abstract[158]	new[158]	_	_
24-3	2816-2826	baroreflex	abstract[158]|place|abstract[160]	new[158]|giv|new[160]	coref|coref	25-16|9-11[0_160]
24-4	2827-2838	sensitivity	abstract[158]|abstract[160]	new[158]|new[160]	_	_
24-5	2839-2841	is	_	_	_	_
24-6	2842-2850	involved	_	_	_	_
24-7	2851-2853	in	_	_	_	_
24-8	2854-2857	the	abstract[161]	giv[161]	_	_
24-9	2858-2876	sympathoexcitatory	abstract[161]	giv[161]	_	_
24-10	2877-2880	and	abstract[161]	giv[161]	_	_
24-11	2881-2899	sympathoinhibitory	abstract[161]	giv[161]	_	_
24-12	2900-2907	effects	abstract[161]	giv[161]	_	_
24-13	2908-2910	of	abstract[161]	giv[161]	_	_
24-14	2911-2920	metabolic	abstract[161]|abstract[162]	giv[161]|new[162]	_	_
24-15	2921-2930	syndromes	abstract[161]|abstract[162]	giv[161]|new[162]	_	_
24-16	2931-2932	.	_	_	_	_

#Text=A previous study showed that hypertriglyceridemia may be the main contributory factor associated with impaired baroreflex sensitivity during a metabolic syndrome .
25-1	2933-2934	A	abstract[163]	giv[163]	coref	28-4[181_163]
25-2	2935-2943	previous	abstract[163]	giv[163]	_	_
25-3	2944-2949	study	abstract[163]	giv[163]	_	_
25-4	2950-2956	showed	_	_	_	_
25-5	2957-2961	that	_	_	_	_
25-6	2962-2982	hypertriglyceridemia	abstract	giv	coref	25-9[165_0]
25-7	2983-2986	may	_	_	_	_
25-8	2987-2989	be	_	_	_	_
25-9	2990-2993	the	abstract[165]	giv[165]	_	_
25-10	2994-2998	main	abstract[165]	giv[165]	_	_
25-11	2999-3011	contributory	abstract[165]	giv[165]	_	_
25-12	3012-3018	factor	abstract[165]	giv[165]	_	_
25-13	3019-3029	associated	abstract[165]	giv[165]	_	_
25-14	3030-3034	with	abstract[165]	giv[165]	_	_
25-15	3035-3043	impaired	abstract[165]|abstract[167]	giv[165]|giv[167]	coref	29-11[193_0]
25-16	3044-3054	baroreflex	abstract[165]|place|abstract[167]	giv[165]|giv|giv[167]	coref	29-12
25-17	3055-3066	sensitivity	abstract[165]|abstract[167]	giv[165]|giv[167]	_	_
25-18	3067-3073	during	abstract[165]|abstract[167]	giv[165]|giv[167]	_	_
25-19	3074-3075	a	abstract[165]|abstract[167]|abstract[168]	giv[165]|giv[167]|new[168]	_	_
25-20	3076-3085	metabolic	abstract[165]|abstract[167]|abstract[168]	giv[165]|giv[167]|new[168]	_	_
25-21	3086-3094	syndrome	abstract[165]|abstract[167]|abstract[168]	giv[165]|giv[167]|new[168]	_	_
25-22	3095-3096	.	_	_	_	_

#Text=Soncrant et al. reported that elevated BP was increased by sympathoexcitation in 20 % fructose-induced , salt-sensitive , hypertensive rats .
26-1	3097-3105	Soncrant	person	new	_	_
26-2	3106-3108	et	_	_	_	_
26-3	3109-3112	al.	_	_	_	_
26-4	3113-3121	reported	_	_	_	_
26-5	3122-3126	that	_	_	_	_
26-6	3127-3135	elevated	abstract[170]	giv[170]	ana	27-1[0_170]
26-7	3136-3138	BP	abstract[170]	giv[170]	_	_
26-8	3139-3142	was	_	_	_	_
26-9	3143-3152	increased	_	_	_	_
26-10	3153-3155	by	_	_	_	_
26-11	3156-3174	sympathoexcitation	abstract	new	coref	28-20
26-12	3175-3177	in	_	_	_	_
26-13	3178-3180	20	animal[172]	giv[172]	coref	28-25[187_172]
26-14	3181-3182	%	animal[172]	giv[172]	_	_
26-15	3183-3199	fructose-induced	animal[172]	giv[172]	_	_
26-16	3200-3201	,	animal[172]	giv[172]	_	_
26-17	3202-3216	salt-sensitive	animal[172]	giv[172]	_	_
26-18	3217-3218	,	animal[172]	giv[172]	_	_
26-19	3219-3231	hypertensive	animal[172]	giv[172]	_	_
26-20	3232-3236	rats	animal[172]	giv[172]	_	_
26-21	3237-3238	.	_	_	_	_

#Text=It has been shown that the ingestion of fructose altered the secretion of hormones that regulate energy balance associated with increased SNA .
27-1	3239-3241	It	abstract	giv	coref	30-29[207_0]
27-2	3242-3245	has	_	_	_	_
27-3	3246-3250	been	_	_	_	_
27-4	3251-3256	shown	_	_	_	_
27-5	3257-3261	that	_	_	_	_
27-6	3262-3265	the	event[174]	new[174]	_	_
27-7	3266-3275	ingestion	event[174]	new[174]	_	_
27-8	3276-3278	of	event[174]	new[174]	_	_
27-9	3279-3287	fructose	event[174]|abstract	new[174]|giv	coref	29-7
27-10	3288-3295	altered	_	_	_	_
27-11	3296-3299	the	abstract[176]	new[176]	_	_
27-12	3300-3309	secretion	abstract[176]	new[176]	_	_
27-13	3310-3312	of	abstract[176]	new[176]	_	_
27-14	3313-3321	hormones	abstract[176]|substance[177]	new[176]|new[177]	_	_
27-15	3322-3326	that	abstract[176]|substance[177]	new[176]|new[177]	_	_
27-16	3327-3335	regulate	abstract[176]|substance[177]	new[176]|new[177]	_	_
27-17	3336-3342	energy	abstract[176]|substance[177]|abstract|abstract[179]	new[176]|new[177]|new|new[179]	_	_
27-18	3343-3350	balance	abstract[176]|substance[177]|abstract[179]	new[176]|new[177]|new[179]	_	_
27-19	3351-3361	associated	_	_	_	_
27-20	3362-3366	with	_	_	_	_
27-21	3367-3376	increased	abstract[180]	giv[180]	coref	30-23[0_180]
27-22	3377-3380	SNA	abstract[180]	giv[180]	_	_
27-23	3381-3382	.	_	_	_	_

#Text=However , in the current study , although a DGAT1 inhibitor was administered orally to block triglycerides production , sympathoexcitation was not inhibited in fructose-fed rats .
28-1	3383-3390	However	_	_	_	_
28-2	3391-3392	,	_	_	_	_
28-3	3393-3395	in	_	_	_	_
28-4	3396-3399	the	abstract[181]	giv[181]	coref	41-8[254_181]
28-5	3400-3407	current	abstract[181]	giv[181]	_	_
28-6	3408-3413	study	abstract[181]	giv[181]	_	_
28-7	3414-3415	,	_	_	_	_
28-8	3416-3424	although	_	_	_	_
28-9	3425-3426	a	abstract[183]	giv[183]	_	_
28-10	3427-3432	DGAT1	abstract|abstract[183]	giv|giv[183]	_	_
28-11	3433-3442	inhibitor	abstract[183]	giv[183]	_	_
28-12	3443-3446	was	_	_	_	_
28-13	3447-3459	administered	_	_	_	_
28-14	3460-3466	orally	_	_	_	_
28-15	3467-3469	to	_	_	_	_
28-16	3470-3475	block	_	_	_	_
28-17	3476-3489	triglycerides	substance|abstract[185]	new|new[185]	_	_
28-18	3490-3500	production	abstract[185]	new[185]	_	_
28-19	3501-3502	,	_	_	_	_
28-20	3503-3521	sympathoexcitation	abstract	giv	_	_
28-21	3522-3525	was	_	_	_	_
28-22	3526-3529	not	_	_	_	_
28-23	3530-3539	inhibited	_	_	_	_
28-24	3540-3542	in	_	_	_	_
28-25	3543-3555	fructose-fed	animal[187]	giv[187]	_	_
28-26	3556-3560	rats	animal[187]	giv[187]	_	_
28-27	3561-3562	.	_	_	_	_

#Text=Dos Santos et al indicated that fructose consumption similarly reduced both baroreflex sensitivity and activity .
29-1	3563-3566	Dos	person[188]	new[188]	_	_
29-2	3567-3573	Santos	person[188]	new[188]	_	_
29-3	3574-3576	et	_	_	_	_
29-4	3577-3579	al	person	new	_	_
29-5	3580-3589	indicated	_	_	_	_
29-6	3590-3594	that	_	_	_	_
29-7	3595-3603	fructose	abstract|abstract[191]	giv|giv[191]	coref	30-6
29-8	3604-3615	consumption	abstract[191]	giv[191]	_	_
29-9	3616-3625	similarly	_	_	_	_
29-10	3626-3633	reduced	_	_	_	_
29-11	3634-3638	both	abstract[193]|abstract[194]	giv[193]|giv[194]	coref	42-13[0_193]
29-12	3639-3649	baroreflex	place|abstract[193]|abstract[194]	giv|giv[193]|giv[194]	coref	30-17
29-13	3650-3661	sensitivity	abstract[193]|abstract[194]	giv[193]|giv[194]	_	_
29-14	3662-3665	and	abstract[194]	giv[194]	_	_
29-15	3666-3674	activity	abstract[194]|abstract	giv[194]|new	coref	35-9[213_0]
29-16	3675-3676	.	_	_	_	_

#Text=Our research further indicated that fructose intake may reduce NO levels in the NTS and cause baroreflex dysfunction , which further stimulates SNA and induces the development of high BP (
30-1	3677-3680	Our	person|abstract[197]	giv|new[197]	ana	41-8
30-2	3681-3689	research	abstract[197]	new[197]	_	_
30-3	3690-3697	further	_	_	_	_
30-4	3698-3707	indicated	_	_	_	_
30-5	3708-3712	that	_	_	_	_
30-6	3713-3721	fructose	abstract|event[199]	giv|giv[199]	coref	44-4
30-7	3722-3728	intake	event[199]	giv[199]	_	_
30-8	3729-3732	may	_	_	_	_
30-9	3733-3739	reduce	_	_	_	_
30-10	3740-3742	NO	substance|abstract[201]	new|giv[201]	coref	35-5[211_201]
30-11	3743-3749	levels	abstract[201]	giv[201]	_	_
30-12	3750-3752	in	_	_	_	_
30-13	3753-3756	the	abstract[202]	giv[202]	_	_
30-14	3757-3760	NTS	abstract[202]	giv[202]	_	_
30-15	3761-3764	and	_	_	_	_
30-16	3765-3770	cause	_	_	_	_
30-17	3771-3781	baroreflex	place|abstract[204]	giv|new[204]	coref	42-12
30-18	3782-3793	dysfunction	abstract[204]	new[204]	_	_
30-19	3794-3795	,	abstract[204]	new[204]	_	_
30-20	3796-3801	which	abstract[204]	new[204]	_	_
30-21	3802-3809	further	abstract[204]	new[204]	_	_
30-22	3810-3820	stimulates	abstract[204]	new[204]	_	_
30-23	3821-3824	SNA	abstract[204]|abstract	new[204]|giv	_	_
30-24	3825-3828	and	abstract[204]	new[204]	_	_
30-25	3829-3836	induces	abstract[204]	new[204]	_	_
30-26	3837-3840	the	abstract[204]|event[206]	new[204]|new[206]	_	_
30-27	3841-3852	development	abstract[204]|event[206]	new[204]|new[206]	_	_
30-28	3853-3855	of	abstract[204]|event[206]	new[204]|new[206]	_	_
30-29	3856-3860	high	abstract[204]|event[206]|abstract[207]	new[204]|new[206]|giv[207]	coref	38-14[0_207]
30-30	3861-3863	BP	abstract[204]|event[206]|abstract[207]	new[204]|new[206]|giv[207]	_	_
30-31	3864-3865	(	_	_	_	_

#Text=Figure 4
31-1	3866-3872	Figure	abstract[208]	new[208]	_	_
31-2	3873-3874	4	abstract[208]	new[208]	_	_

#Text=and
32-1	3875-3878	and	_	_	_	_

#Text=Figure 5
33-1	3879-3885	Figure	abstract[209]	new[209]	_	_
33-2	3886-3887	5	abstract[209]	new[209]	_	_

#Text=) .
34-1	3888-3889	)	_	_	_	_
34-2	3890-3891	.	_	_	_	_

#Text=Generally , anesthetics affect the basal levels of sympathetic nerve activity to regulate blood pressure , which plays an important role in controlling cardiovascular function .
35-1	3892-3901	Generally	_	_	_	_
35-2	3902-3903	,	_	_	_	_
35-3	3904-3915	anesthetics	abstract	new	coref	36-26[226_0]
35-4	3916-3922	affect	_	_	_	_
35-5	3923-3926	the	abstract[211]	giv[211]	_	_
35-6	3927-3932	basal	abstract[211]	giv[211]	_	_
35-7	3933-3939	levels	abstract[211]	giv[211]	_	_
35-8	3940-3942	of	abstract[211]	giv[211]	_	_
35-9	3943-3954	sympathetic	abstract[211]|abstract[213]	giv[211]|giv[213]	coref	40-3[249_213]
35-10	3955-3960	nerve	abstract[211]|abstract|abstract[213]	giv[211]|new|giv[213]	coref	40-4
35-11	3961-3969	activity	abstract[211]|abstract[213]	giv[211]|giv[213]	_	_
35-12	3970-3972	to	_	_	_	_
35-13	3973-3981	regulate	_	_	_	_
35-14	3982-3987	blood	substance|abstract[215]	new|new[215]	_	_
35-15	3988-3996	pressure	abstract[215]	new[215]	_	_
35-16	3997-3998	,	abstract[215]	new[215]	_	_
35-17	3999-4004	which	abstract[215]	new[215]	_	_
35-18	4005-4010	plays	abstract[215]	new[215]	_	_
35-19	4011-4013	an	abstract[215]|abstract[216]	new[215]|new[216]	_	_
35-20	4014-4023	important	abstract[215]|abstract[216]	new[215]|new[216]	_	_
35-21	4024-4028	role	abstract[215]|abstract[216]	new[215]|new[216]	_	_
35-22	4029-4031	in	abstract[215]|abstract[216]	new[215]|new[216]	_	_
35-23	4032-4043	controlling	abstract[215]|abstract[216]	new[215]|new[216]	_	_
35-24	4044-4058	cardiovascular	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	coref	40-7[250_217]
35-25	4059-4067	function	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
35-26	4068-4069	.	_	_	_	_

#Text=Sun et al. indicated that anesthesia attenuated the excitatory response of RSNA and HR to anaphylactic hypotension , while these excitatory responses were attenuated by anesthetics in the order ketamine-xylazine >
36-1	4070-4073	Sun	person	new	_	_
36-2	4074-4076	et	_	_	_	_
36-3	4077-4080	al.	_	_	_	_
36-4	4081-4090	indicated	_	_	_	_
36-5	4091-4095	that	_	_	_	_
36-6	4096-4106	anesthesia	abstract	new	coref	38-6[232_0]
36-7	4107-4117	attenuated	_	_	_	_
36-8	4118-4121	the	abstract[220]	new[220]	_	_
36-9	4122-4132	excitatory	abstract[220]	new[220]	_	_
36-10	4133-4141	response	abstract[220]	new[220]	_	_
36-11	4142-4144	of	abstract[220]	new[220]	_	_
36-12	4145-4149	RSNA	abstract[220]|abstract|abstract[222]	new[220]|new|new[222]	coref|coref	42-10|42-10[259_222]
36-13	4150-4153	and	abstract[220]|abstract[222]	new[220]|new[222]	_	_
36-14	4154-4156	HR	abstract[220]|abstract[222]|abstract	new[220]|new[222]|new	_	_
36-15	4157-4159	to	_	_	_	_
36-16	4160-4172	anaphylactic	abstract[224]	new[224]	_	_
36-17	4173-4184	hypotension	abstract[224]	new[224]	_	_
36-18	4185-4186	,	_	_	_	_
36-19	4187-4192	while	_	_	_	_
36-20	4193-4198	these	abstract[225]	new[225]	_	_
36-21	4199-4209	excitatory	abstract[225]	new[225]	_	_
36-22	4210-4219	responses	abstract[225]	new[225]	_	_
36-23	4220-4224	were	_	_	_	_
36-24	4225-4235	attenuated	_	_	_	_
36-25	4236-4238	by	_	_	_	_
36-26	4239-4250	anesthetics	abstract[226]	giv[226]	coref	39-4[0_226]
36-27	4251-4253	in	abstract[226]	giv[226]	_	_
36-28	4254-4257	the	abstract[226]|abstract[227]|abstract[228]	giv[226]|new[227]|new[228]	_	_
36-29	4258-4263	order	abstract[226]|abstract[227]|abstract[228]	giv[226]|new[227]|new[228]	_	_
36-30	4264-4281	ketamine-xylazine	abstract[226]|abstract[228]	giv[226]|new[228]	_	_
36-31	4282-4283	>	_	_	_	_

#Text=urethane = pentobarbital .
37-1	4284-4292	urethane	substance	new	_	_
37-2	4293-4294	=	_	_	_	_
37-3	4295-4308	pentobarbital	abstract	new	_	_
37-4	4309-4310	.	_	_	_	_

#Text=Bencze et al. found that pentobarbital anesthesia had a modest influence on the BP level and its maintenance by the above vasoactive systems .
38-1	4311-4317	Bencze	person	new	_	_
38-2	4318-4320	et	_	_	_	_
38-3	4321-4324	al.	_	_	_	_
38-4	4325-4330	found	_	_	_	_
38-5	4331-4335	that	_	_	_	_
38-6	4336-4349	pentobarbital	abstract[232]	giv[232]	_	_
38-7	4350-4360	anesthesia	abstract[232]	giv[232]	_	_
38-8	4361-4364	had	_	_	_	_
38-9	4365-4366	a	abstract[233]	new[233]	_	_
38-10	4367-4373	modest	abstract[233]	new[233]	_	_
38-11	4374-4383	influence	abstract[233]	new[233]	_	_
38-12	4384-4386	on	abstract[233]	new[233]	_	_
38-13	4387-4390	the	abstract[233]|abstract[235]	new[233]|giv[235]	ana	38-17[0_235]
38-14	4391-4393	BP	abstract[233]|abstract|abstract[235]	new[233]|giv|giv[235]	coref	42-5
38-15	4394-4399	level	abstract[233]|abstract[235]	new[233]|giv[235]	_	_
38-16	4400-4403	and	_	_	_	_
38-17	4404-4407	its	abstract|abstract[237]	giv|new[237]	_	_
38-18	4408-4419	maintenance	abstract[237]	new[237]	_	_
38-19	4420-4422	by	abstract[237]	new[237]	_	_
38-20	4423-4426	the	abstract[237]|abstract[238]	new[237]|new[238]	_	_
38-21	4427-4432	above	abstract[237]|abstract[238]	new[237]|new[238]	_	_
38-22	4433-4443	vasoactive	abstract[237]|abstract[238]	new[237]|new[238]	_	_
38-23	4444-4451	systems	abstract[237]|abstract[238]	new[237]|new[238]	_	_
38-24	4452-4453	.	_	_	_	_

#Text=In addition , anesthetics may inhibit the primary area in the baroreceptor reflex pathway of the central nervous system , resulting in attenuation of the baroreceptor reflex .
39-1	4454-4456	In	_	_	_	_
39-2	4457-4465	addition	_	_	_	_
39-3	4466-4467	,	_	_	_	_
39-4	4468-4479	anesthetics	abstract	giv	_	_
39-5	4480-4483	may	_	_	_	_
39-6	4484-4491	inhibit	_	_	_	_
39-7	4492-4495	the	place[240]	new[240]	_	_
39-8	4496-4503	primary	place[240]	new[240]	_	_
39-9	4504-4508	area	place[240]	new[240]	_	_
39-10	4509-4511	in	place[240]	new[240]	_	_
39-11	4512-4515	the	place[240]|abstract[243]	new[240]|new[243]	_	_
39-12	4516-4528	baroreceptor	place[240]|person|abstract[243]	new[240]|new|new[243]	coref	39-26
39-13	4529-4535	reflex	place[240]|abstract|abstract[243]	new[240]|new|new[243]	coref	39-25[247_0]
39-14	4536-4543	pathway	place[240]|abstract[243]	new[240]|new[243]	_	_
39-15	4544-4546	of	place[240]|abstract[243]	new[240]|new[243]	_	_
39-16	4547-4550	the	place[240]|abstract[243]|abstract[244]	new[240]|new[243]|giv[244]	_	_
39-17	4551-4558	central	place[240]|abstract[243]|abstract[244]	new[240]|new[243]|giv[244]	_	_
39-18	4559-4566	nervous	place[240]|abstract[243]|abstract[244]	new[240]|new[243]|giv[244]	_	_
39-19	4567-4573	system	place[240]|abstract[243]|abstract[244]	new[240]|new[243]|giv[244]	_	_
39-20	4574-4575	,	_	_	_	_
39-21	4576-4585	resulting	_	_	_	_
39-22	4586-4588	in	_	_	_	_
39-23	4589-4600	attenuation	abstract[245]	new[245]	_	_
39-24	4601-4603	of	abstract[245]	new[245]	_	_
39-25	4604-4607	the	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
39-26	4608-4620	baroreceptor	abstract[245]|person|abstract[247]	new[245]|giv|giv[247]	_	_
39-27	4621-4627	reflex	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
39-28	4628-4629	.	_	_	_	_

#Text=Therefore , sympathetic nerve activity and cardiovascular function may be affected by the anesthetic .
40-1	4630-4639	Therefore	_	_	_	_
40-2	4640-4641	,	_	_	_	_
40-3	4642-4653	sympathetic	abstract[249]	giv[249]	_	_
40-4	4654-4659	nerve	abstract|abstract[249]	giv|giv[249]	_	_
40-5	4660-4668	activity	abstract[249]	giv[249]	_	_
40-6	4669-4672	and	_	_	_	_
40-7	4673-4687	cardiovascular	abstract[250]	giv[250]	_	_
40-8	4688-4696	function	abstract[250]	giv[250]	_	_
40-9	4697-4700	may	_	_	_	_
40-10	4701-4703	be	_	_	_	_
40-11	4704-4712	affected	_	_	_	_
40-12	4713-4715	by	_	_	_	_
40-13	4716-4719	the	abstract[251]	new[251]	coref	42-18[263_251]
40-14	4720-4730	anesthetic	abstract[251]	new[251]	_	_
40-15	4731-4732	.	_	_	_	_

#Text=However , there were some limitations to our study .
41-1	4733-4740	However	_	_	_	_
41-2	4741-4742	,	_	_	_	_
41-3	4743-4748	there	_	_	_	_
41-4	4749-4753	were	_	_	_	_
41-5	4754-4758	some	abstract[252]	new[252]	_	_
41-6	4759-4770	limitations	abstract[252]	new[252]	_	_
41-7	4771-4773	to	abstract[252]	new[252]	_	_
41-8	4774-4777	our	abstract[252]|person|abstract[254]	new[252]|giv|giv[254]	ana|coref	42-3|43-10[267_254]
41-9	4778-4783	study	abstract[252]|abstract[254]	new[252]|giv[254]	_	_
41-10	4784-4785	.	_	_	_	_

#Text=First , we measured BP during consciousness , whereas RSNA and baroreflex sensitivity measurements were performed under the anesthetic .
42-1	4786-4791	First	_	_	_	_
42-2	4792-4793	,	_	_	_	_
42-3	4794-4796	we	person	giv	ana	43-3
42-4	4797-4805	measured	_	_	_	_
42-5	4806-4808	BP	abstract	giv	_	_
42-6	4809-4815	during	_	_	_	_
42-7	4816-4829	consciousness	abstract	new	_	_
42-8	4830-4831	,	_	_	_	_
42-9	4832-4839	whereas	_	_	_	_
42-10	4840-4844	RSNA	abstract|abstract[259]	giv|giv[259]	_	_
42-11	4845-4848	and	abstract[259]	giv[259]	_	_
42-12	4849-4859	baroreflex	abstract[259]|place	giv[259]|giv	_	_
42-13	4860-4871	sensitivity	abstract|abstract[262]	giv|new[262]	_	_
42-14	4872-4884	measurements	abstract[262]	new[262]	_	_
42-15	4885-4889	were	_	_	_	_
42-16	4890-4899	performed	_	_	_	_
42-17	4900-4905	under	_	_	_	_
42-18	4906-4909	the	abstract[263]	giv[263]	_	_
42-19	4910-4920	anesthetic	abstract[263]	giv[263]	_	_
42-20	4921-4922	.	_	_	_	_

#Text=Second , our sample size was relatively small and the study used nonparametric methods for analysis .
43-1	4923-4929	Second	_	_	_	_
43-2	4930-4931	,	_	_	_	_
43-3	4932-4935	our	person|abstract[266]	giv|new[266]	_	_
43-4	4936-4942	sample	object|abstract[266]	new|new[266]	_	_
43-5	4943-4947	size	abstract[266]	new[266]	_	_
43-6	4948-4951	was	_	_	_	_
43-7	4952-4962	relatively	_	_	_	_
43-8	4963-4968	small	_	_	_	_
43-9	4969-4972	and	_	_	_	_
43-10	4973-4976	the	abstract[267]	giv[267]	_	_
43-11	4977-4982	study	abstract[267]	giv[267]	_	_
43-12	4983-4987	used	_	_	_	_
43-13	4988-5001	nonparametric	abstract[268]	new[268]	_	_
43-14	5002-5009	methods	abstract[268]	new[268]	_	_
43-15	5010-5013	for	abstract[268]	new[268]	_	_
43-16	5014-5022	analysis	abstract[268]|abstract	new[268]|new	_	_
43-17	5023-5024	.	_	_	_	_

#Text=Third , the fructose group was used as the control group only on day 0 .
44-1	5025-5030	Third	_	_	_	_
44-2	5031-5032	,	_	_	_	_
44-3	5033-5036	the	animal[271]	new[271]	_	_
44-4	5037-5045	fructose	abstract|animal[271]	giv|new[271]	_	_
44-5	5046-5051	group	animal[271]	new[271]	_	_
44-6	5052-5055	was	_	_	_	_
44-7	5056-5060	used	_	_	_	_
44-8	5061-5063	as	_	_	_	_
44-9	5064-5067	the	person[272]	new[272]	_	_
44-10	5068-5075	control	person[272]	new[272]	_	_
44-11	5076-5081	group	person[272]	new[272]	_	_
44-12	5082-5086	only	time[273]	new[273]	_	_
44-13	5087-5089	on	time[273]	new[273]	_	_
44-14	5090-5093	day	time[273]	new[273]	_	_
44-15	5094-5095	0	time[273]	new[273]	_	_
44-16	5096-5097	.	_	_	_	_
